financetom
Market
financetom
/
Market
/
Here is why banking stocks declined after the RBI MPC announcements
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Here is why banking stocks declined after the RBI MPC announcements
Feb 8, 2023 4:31 AM

Banking stocks trimmed early gains in morning trade on Wednesday with the Nifty Bank declining around 390 points from the day’s high after the RBI raised the key short-term lending rate by 25 basis points to a four-year high of 6.5 percent. Among major losers, Bank of Baroda declined by 0.53 percent to Rs 167.65, IDFC First Bank by 0.42 percent to Rs 59.65 and Axis Bank by 0.37 percent to Rs 875.85 on NSE.

Share Market Live

NSE

ICICI Bank, Bandhan Bank, PNB, SBI, HDFC Bank and IndusInd Bank also trimmed gains following the announcement of the RBI policy.

The Nifty Bank index opened strong and touched a high of 41,791.95 in morning deals ahead of the announcement. It later fell to a low of 41,403.05.

BSE Bankex also retreated from the day's high of 47,295.78 to trade marginally up at 47,006.05.

Earlier in the day, RBI Governor Shaktikanta Das announced a repo rate hike of 25 basis points to 6.50 percent, the highest since February 2019. Moreover, the RBI pegged India's economic growth lower at 6.4 percent in FY24 against 7 percent in FY23 due to risks from geo-political tension and tightening global financial conditions.

The RBI said that it would keep a strong vigil on the inflation outlook as core inflation is expected to remain sticky. Inflation is expected to moderate but will remain above the targeted 4 percent level in the next fiscal year, the RBI said in its policy statement. Retail inflation will average 6.5 per cent in 2022-23 and moderate to 5.3 per cent in 2023-24.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wall Street Declines After Trump's Fresh Tariff Threats; Apple Falls 3%
Wall Street Declines After Trump's Fresh Tariff Threats; Apple Falls 3%
May 26, 2025
04:59 PM EDT, 05/23/2025 (MT Newswires) -- US benchmark equity indexes declined on Friday as President Donald Trump's tariff threats against the European Union and Apple ( AAPL ) refueled concerns about a trade war. The Nasdaq Composite fell 1% at 18,737.2. The S&P 500 dropped 0.7% to 5,802.8, marking the fourth straight day of declines, while the Dow Jones...
S&P 500 Posts Weekly Drop Amid Tariff Threats; Energy Leads Broad Decline
S&P 500 Posts Weekly Drop Amid Tariff Threats; Energy Leads Broad Decline
May 26, 2025
04:46 PM EDT, 05/23/2025 (MT Newswires) -- The Standard & Poor's 500 index fell 2.6% this week, pushing the market benchmark back into the red for the year, amid a fresh round of tariff threats from the Trump administration. The market benchmark ended the week at 5,802.82. The measure is still in positive territory for May with a month-to-date gain...
Wall St Week Ahead-Nvidia earnings in focus as rising US yields, debt rattle markets
Wall St Week Ahead-Nvidia earnings in focus as rising US yields, debt rattle markets
May 26, 2025
* Nvidia ( NVDA ) results due on Wednesday, last of Magnificent 7 earnings * 30-year US Treasury yield tops 5% during week * After rebound, S&P 500 down over 5% from Feb record high By Lewis Krauskopf NEW YORK, May 23 (Reuters) - An earnings report from semiconductor giant and artificial intelligence bellwether Nvidia ( NVDA ) takes center...
Boundless Bio's Portfolio Adjustments and Streamlined Operations Boost Cash Runway
Boundless Bio's Portfolio Adjustments and Streamlined Operations Boost Cash Runway
May 26, 2025
04:37 PM EDT, 05/23/2025 (MT Newswires) -- Boundless Bio ( BOLD ) said late Friday it optimized its portfolio and streamlined operations, including a one-third reduction of its workforce to drive long-term value creation. The company discontinued the monotherapy and combination arms of BBI-355 candidate in Potentiate clinical trial due to toxicity concerns and a narrow therapeutic index, according to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved